Biostage (NSDQ:BSTG) this week announced that its Cellspan Esophageal Implant investigational new drug application won FDA approval.
The Cellspan Esophageal Implant is designed to treat patients with end-stage esophageal disease that require segmental surgical resection to repair diseased tissue.
Biostage announced the first patient was treated with the esophageal implant in August 2017. The device was implanted in a 75-year old male patient who had a life-threatening cancerous mass in his chest.